参考文献
[1]马亚琪，王昀，刘爱军.WHO（2014）卵巢肿瘤组织学分类[J].诊断病理学杂志，2014，21（8）：530-531.
[2]Reid B M,Permuth J B,Sellers TA.Epidemiology of ovarian cancer:a review[J].Cancer Biol Med,2017,14(1):9-32.
[3]Hauptmann S,Friedrich K,Redline R,et al.Ovarian borderline tumors in the 2014 WHO classification:evolving concepts and diagnostic criteria[J].Virchows Arch,2017,470(2):125-142.
[4]Prat J.Ovarian,fallopian tube and peritoneal cancer staging:Rationale and explanation of new FIGO staging 2013[J].Best Pract Res Clin Obstet Gynaecol,2015,29(6):858-869.
[5]Wright J D,Shah M,Mathew L,et al.Fertility preservation in young women withepithelial ovarian cancer[J].Cancer,2009,115(18):4118-4126.
[6]Satoh T,Hatae M,Watanabe Y,et al.Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer:a proposal for patient selection[J].J Clin Oncol,2010,28(10):1727-1732.
[7]Earle C C,Schrag D,Neville B A,et al.Eあect of surgeon specialty on processes of care and outcomes for ovarian cancer patients[J].J Natl Cancer Inst,2006,98(3):172-180.
[8]Giede K C,Kieser K,Dodge J,et al.Who should operate on patients with ovarian cancer? An evidence-based review[J].Gynecol Oncol,2005,99(2):447-461.
[9]Engelen M J,Kos H E,Willemse P H,et al.Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma[J].Cancer,2006,106(3):589-598.
[10]Wright A A,Bohlke K,Armstrong D K,et al.Neoadjuvant Chemotherapy for Newly Diagnosed,Advanced Ovarian Cancer:Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline[J].J Clin Oncol,2016,34(28):3460-3473.
[11]Bois du A,Weber B,Rochon J,et al.Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer:a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l’Etude des Cancers Ovariens[J].J Clin Oncol,2006,24(7):1127-1135.
[12]Bookman M A,Brady M F,McGuire WP,et al.Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer:a Phase III Trial of the Gynecologic Cancer Intergroup[J].J Clin Oncol,2009,27(9):1419-1425.
[13]Bolis G,Scarfone G,Raspagliesi F,et al.Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage IIIIV epithelial ovarian cancer a multicenter,randomized study[J].Eur J Cancer,2010,46(16):2905-2912.
[14]Pignata S,Scambia G,Ferrandina G,et al.Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer:the MITO-2 randomized phase III trial[J].J Clin Oncol,2011,29(27):3628-3635.(https://www.daowen.com)
[15]Katsumata N,Yasuda M,Isonishi S,et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian,fallopian tube,or primary peritoneal cancer(JGOG 3016):a randomised,controlled,open-label trial[J].Lancet Oncol,2013,14(10):1020-1026.
[16]Burger R A,Brady M F,Bookman M A,et al.Incorporation of bevacizumab in the primary treatment of ovarian cancer[J].N Engl J Med,2011,365(26):2473-2483.
[17]Perren T J,Swart A M,Pfisterer J,et al.A phase 3 trial of bevacizumab in ovarian cancer[J].N Engl J Med,2011,365(26):2484-2496.
[18]Ferriss J S,Java J J,Bookman M A,et al.Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian,fallopian tube and peritoneal cancers:an NRG Oncology/GOG study[J].Gynecol Oncol,2015,139(1):17-22.
[19]Hall M,Gourley C,McNeish I,et al.Targeted anti-vascular therapies for ovarian cancer:current evidence[J].Br J Cancer,2013,108(2):250-258.
[20]Bois du A,Floquet A,Kim J W,et al.Incorporation of pazopanib in maintenance therapy of ovarian cancer[J].J Clin Oncol,2014,32(30):3374-3382.
[21]Kim J W,Mahner S,Wu L Y,et al.Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer:Results From AGO-OVAR16 and an East Asian Study[J].Int J Gynecol Cancer,2018,28(1):2-10.
[22]Ledermann J,Harter P,Gourley C,et al.Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer[J].NEJM,2012,366(15):1382-1392.
[23]Swisher E M,Lin K K,Oza A M,et al.Rucaparib in relapsed,platinum-sensitive high-grade ovarian carcinoma(ARIEL2 Part 1):an international,multicentre,openlabel,phase 2 trial[J].Lancet Oncol,2017,18(1):75-87.
[24]Mirza M R,Monk B J,Herrstedt J,et al.Niraparib maintenance therapy in platinum-sensitive,recurrent ovarian cancer[J].N Engl J Med,2016,375:2154-2164.
[25]Aghajanian C,Blank S V,Goあ B A,et al.OCEANS:a randomized,double-blind,placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian,primary peritoneal,or fallopian tube cancer[J].J Clin Oncol,2012,30(17):2039-2045.
[26]Aghajanian C,Goあ B,Nycum L R,et al.Final overall survival and safety analysis of OCEANS,a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer[J].Gynecol Oncol,2015,139(1):10-16.
[27]Ledermann J A,Embleton A C,Raja F,et al.Cediranib in patients with relapsed platinum-sensitive ovarian cancer(ICON6):a randomised,double-blind,placebocontrolled phase 3 trial[J].Lancet,2016,387(10023):1066-1074.